Related Experiment Video
Updated: Sep 26, 2025
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma
Giuliana Ferrante1, Salvatore Fasola2, Velia Malizia2
1Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Division, University of Verona, 37134 Verona, Italy.
Insights
Personalized medicine offers tailored treatments for childhood asthma by using genomics and pharmacogenomics. This approach aims to improve asthma control and reduce future health risks in children.
Area of Science:
- Pediatric Pulmonology
- Genomics and Personalized Medicine
- Pharmacogenomics
Background:
- Childhood asthma is a complex, heterogeneous disease with many children experiencing uncontrolled symptoms.
- Current treatment approaches may not be sufficient for all children, necessitating individualized strategies.
- Personalized medicine is emerging as a viable approach for optimizing health outcomes across various diseases.
Purpose of the Study:
- To explore the potential of genomics and pharmacogenomics in improving childhood asthma control.
- To highlight the role of pharmacogenomics in identifying novel molecular mechanisms and biomarkers for asthma treatment.
- To emphasize the need for individualized treatment strategies in pediatric asthma.
Main Methods:
- Leveraging advancements in genomics and pharmacogenomics for asthma research.
- Utilizing high-throughput technologies for comprehensive data acquisition.
- Employing patient pheno-endotypization to understand disease heterogeneity.
Main Results:
- Genomics and pharmacogenomics offer promising avenues for achieving better asthma control in children.
- Pharmacogenomics can identify key molecular pathways and biomarkers relevant to asthma pathophysiology.
- Advanced technologies and detailed patient characterization enhance understanding of disease mechanisms.
Conclusions:
- An individualized approach, guided by genomics and pharmacogenomics, is crucial for managing childhood asthma.
- Precision medicine strategies can lead to more effective treatment selection and stratification for pediatric asthma patients.
- Further research integrating high-throughput technologies and pheno-endotypization will refine personalized asthma care.
Abstract:
Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, along with patient pheno-endotypization, will increase our knowledge of several molecular mechanisms involved in asthma pathophysiology and contribute to selecting and stratifying appropriate treatment for each patient.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
12:08Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells
Published on: March 10, 2016
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:28Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
01:29Asthma-I: Introduction
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...